Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 4

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 -  
     - -
     (4,102,495) 
     (4,102,495)
  
    Sale of equity through equity financing facilities, net of costs 
     120,047  
     1,200  
     104,492  
     -  
     - -
     -  
     105,692 
  
    Stock-based compensation expense 
     -  
     -  
     204,533  
     -  
     - -
     -  
     204,533 
  
    Balance at March
31, 2025 (unaudited) 
     14,620,754  
    $146,207  
    $411,296,548  
     22  
    $(85,188)-
    $(410,905,539) 
    $452,028 

See accompanying notes to the unaudited condensed
consolidated financial statements.

6

IMUNON, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

FOR THE THREE MONTHS ENDED MARCH 31, 2024

    Common Stock Outstanding  
    Additional Paid-in  
    Treasury Stock  
    Accumulated Other Comprehensive  
    Accumulated  
    Total Stockholders’ 

    Shares  
    Amount  
    Capital  
    Shares  
    Amount  
    Income  
    Deficit  
    Equity 

    Balance at January 1, 2024 
     9,399,811  
    $93,998  
    $401,500,838  
     22  
    $(85,188) 
    $60,796  
    $(388,182,802) 
    $13,387,642 
  
    Balance  
     9,399,811  
    $93,998  
    $401,500,838  
     22  
    $(85,188) 
    $60,796  
    $(388,182,802) 
    $13,387,642 

    Net loss 
     -  
     -  
     -  
     -  
     -  
     -  
     (4,